Open Access System for Information Sharing

Login Library

 

Article
Cited 5 time in webofscience Cited 6 time in scopus
Metadata Downloads
Full metadata record
Files in This Item:
There are no files associated with this item.
DC FieldValueLanguage
dc.contributor.authorGu, Gyo-Jeong-
dc.contributor.authorAhn, Sang-il-
dc.contributor.authorKim, Ji-Soo-
dc.contributor.authorHong, Chae-Yeon-
dc.contributor.authorLee, Sung-Chan-
dc.contributor.authorChang, Young-Tae-
dc.contributor.authorChoi, Tae Hyun-
dc.contributor.authorKim, Byoung Soo-
dc.contributor.authorYoun, Hyung-Sun-
dc.date.accessioned2018-06-15T05:20:46Z-
dc.date.available2018-06-15T05:20:46Z-
dc.date.created2017-09-08-
dc.date.issued2015-09-
dc.identifier.issn1567-5769-
dc.identifier.urihttps://oasis.postech.ac.kr/handle/2014.oak/50379-
dc.description.abstractToll-like receptors (TLRs) recognize distinct pathogen-associated molecular patterns and play a critical role in innate immune responses. TLR signaling pathways can be largely classified as either myeloid differential factor 88 (MyD88)- or toll-interleukin-1 receptor domain-containing adapter inducing interferon-beta (TRIF)-dependent pathways. Compound of Designation red 10 binding (CDr10b) was synthesized to investigate its role in neuroinflammatory diseases. This study was conducted to determine whether CDr10b can affect TLR signaling pathways. CDr10b suppressed NF-kappa B activation as well as COX-2 and iNOS expression induced by TLR3 or TLR4 agonists. CDr10b also suppressed the activation of interferon regulatory factor 3 (IRF3) and the expression of interferon inducible protein-10 (IP-10) induced by TLR3 or TLR4 agonists. These results indicate that CDr10b can modulate the TRIF-dependent pathway of TLRs and has the potential to become a new therapeutic drug for chronic inflammatory diseases. (C) 2015 Elsevier B.V. All rights reserved.-
dc.languageEnglish-
dc.publisherELSEVIER SCIENCE BV-
dc.relation.isPartOfINTERNATIONAL IMMUNOPHARMACOLOGY-
dc.subjectINTERFERON REGULATORY FACTOR-3-
dc.subjectPATTERN-RECOGNITION RECEPTORS-
dc.subjectINNATE IMMUNITY-
dc.subjectEXPRESSION-
dc.subjectLIPOPOLYSACCHARIDE-
dc.subjectCYCLOOXYGENASE-2-
dc.subjectTRANSCRIPTION-
dc.subject6-SHOGAOL-
dc.subjectKINASE-
dc.titleSuppression of the TRIF-dependent signaling pathway of Toll-like receptor by CDr10b in RAW264.7 macrophages-
dc.typeArticle-
dc.identifier.doi10.1016/j.intimp.2015.05.017-
dc.type.rimsART-
dc.identifier.bibliographicCitationINTERNATIONAL IMMUNOPHARMACOLOGY, v.28, no.1, pp.29 - 33-
dc.identifier.wosid000361413500004-
dc.date.tcdate2019-02-01-
dc.citation.endPage33-
dc.citation.number1-
dc.citation.startPage29-
dc.citation.titleINTERNATIONAL IMMUNOPHARMACOLOGY-
dc.citation.volume28-
dc.contributor.affiliatedAuthorChang, Young-Tae-
dc.identifier.scopusid2-s2.0-84930627553-
dc.description.journalClass1-
dc.description.journalClass1-
dc.description.wostc2-
dc.type.docTypeArticle-
dc.subject.keywordPlusINTERFERON REGULATORY FACTOR-3-
dc.subject.keywordPlusPATTERN-RECOGNITION RECEPTORS-
dc.subject.keywordPlusINNATE IMMUNITY-
dc.subject.keywordPlusEXPRESSION-
dc.subject.keywordPlusLIPOPOLYSACCHARIDE-
dc.subject.keywordPlusCYCLOOXYGENASE-2-
dc.subject.keywordPlusTRANSCRIPTION-
dc.subject.keywordPlus6-SHOGAOL-
dc.subject.keywordPlusKINASE-
dc.subject.keywordAuthorCDr10b-
dc.subject.keywordAuthorToll-like receptor-
dc.subject.keywordAuthorIRF3-
dc.subject.keywordAuthorIP-10-
dc.subject.keywordAuthorTRIF-
dc.relation.journalWebOfScienceCategoryImmunology-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalResearchAreaImmunology-
dc.relation.journalResearchAreaPharmacology & Pharmacy-

qr_code

  • mendeley

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Views & Downloads

Browse